Physician

David Amran, M.D.

According to 2025 Medicare claims, David Amran, M.D. (NPI: 1841294261) practices allergy/immunology in the Houston-Pasadena-The Woodlands, TX market, with the plurality of this provider's patient population coming from Fort Bend, TX. This provider's primary affiliated billing organization is SUGAR LAND ALLERGY, ASTHMA & IMMUNOLOGY CENTER, PA (NPI: 1649274077; TIN: 760542990) and primary practice location at 77479-3153.

Amran's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 355 traditional Medicare patients, billed 128,231 HCPCS/CPT codes, and received $3,243,303 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,395 prescription claims across 269 beneficiaries totaling $755,942 in drug costs, led by Dupixent Syringe (Dupilumab). DME data shows 41 claims. Open Payments data shows 199 records totaling $11,188. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $740,305 to $3,243,303. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $110,773 to $755,942. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $3,989 to $831.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	222	37,905	$740,305
2016	233	35,466	$685,526
2017	259	36,896	$712,050
2018	244	41,293	$865,585
2019	276	59,704	$1,457,463
2020	278	67,528	$1,820,335
2021	417	81,959	$2,213,603
2022	345	115,282	$2,920,154
2023	335	117,897	$2,954,525
2024	355	128,231	$3,243,303

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	185	1,166	$110,773
2016	200	1,227	$170,987
2017	211	1,232	$124,686
2018	232	1,294	$172,323
2019	249	1,387	$268,663
2020	242	1,491	$446,898
2021	300	1,809	$717,166
2022	317	1,967	$934,422
2023	323	1,906	$903,393
2024	269	1,395	$755,942

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	16	169	$106,293
2016	N/R	111	$104,621
2017	15	28	$451
2018	12	35	$569
2019	11	65	$2,025
2020	N/R	11	$288
2021	11	64	$2,708
2022	30	90	$2,489
2023	14	117	$2,468
2024	N/R	41	$1,434

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	191	383	$101
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	265	1,121	$69
95012	Test to measure the level of nitric oxide gas	122	314	$14
95165	Professional service for preparation and provision of 1 or more antigens	162	7,319	$12
95117	Professional service for multiple injections of allergen	183	3,286	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Dupixent Syringe	Dupilumab	31	1,092	$154,186
Xolair	Omalizumab	61	1,708	$147,658
Gamunex-C	Immune Globul G/Gly/Iga Avg 46	19	630	$141,583
Nucala	Mepolizumab	29	840	$107,884
Symbicort	Budesonide/Formoterol Fumarate	68	3,180	$24,112

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7626	Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg	N	N/R	17	$813
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	N/R	24	$621

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	199	$11,188	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for David Amran, M.D.?

Tedicare shows public-source Medicare data for David Amran, M.D. (NPI 1841294261), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David Amran, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to David Amran, M.D.?

David Amran, M.D. is linked to SUGAR LAND ALLERGY, ASTHMA & IMMUNOLOGY CENTER, PA (billing NPI 1649274077) in the available physician profile data.

Does David Amran, M.D. have Open Payments data?

David Amran, M.D. has 199 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.